Zinecard Related Published Studies
Well-designed clinical trials related to Zinecard (Dexrazoxane)
Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. [2010.10]
In vitro and in vivo study on the antioxidant activity of dexrazoxane. [2010.04]
Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy. [2006.04]
Effect of epirubicin-based chemotherapy and dexrazoxane supplementation on QT dispersion in non-Hodgkin lymphoma patients. [2005.12]
The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. [2004.07.08]
Effect of dexrazoxane on homocysteine-induced endothelial dysfunction in normal subjects. [2002.07.01]
Comparative open, randomized, cross-over bioequivalence study of two intravenous dexrazoxane formulations (Cardioxane and ICRF-187) in patients with advanced breast cancer, treated with 5-fluorouracil-doxorubicin-cyclophosphamide (FDC). [1999.01]
Dexrazoxane cardioprotection in advanced breast cancer patients undergoing high-dose epirubicin treatment. [1998.01]
Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas. [1998.01]
Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. [1997.04]
Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. [1996.12]
Dexrazoxane cardioprotection for patients receiving FAC chemotherapy: a pharmacoeconomic evaluation. [1996.11]
Comparative study of the pharmacokinetics and toxicity of high-dose epirubicin with or without dexrazoxane in patients with advanced malignancy. [1994.08]
Well-designed clinical trials possibly related to Zinecard (Dexrazoxane)
Irradiation with and without Razoxane in the Treatment of Incompletely Resected or Inoperable Recurrent Rectal Cancer : Results of a Small Randomized Multicenter Study. [2007.07]
Iron sucrose augments homocysteine-induced endothelial dysfunction in normal subjects. [2006.02]
Single agent epirubicin as first line chemotherapy for metastatic breast cancer patients. [2000.01]
Radiotherapy vs. radiotherapy and razoxane in the treatment of soft tissue sarcomas: final results of a randomized study. [1996.12.01]
Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. [1996.02]
Peri-operative heparin: a possible adjuvant to surgery in colo-rectal cancer? [1993.07]
Responses of liver metastases to radiotherapy and razoxane. [1992.03]
ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. [1992.01]
Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. [1988.09.22]
Other research related to Zinecard (Dexrazoxane)
Dexrazoxane protects breast cancer patients with diabetes from
chemotherapy-induced cardiotoxicity. [2015]
Cardioprotective effect of dexrazoxane in a rat model of myocardial infarction: anti-apoptosis and promoting angiogenesis. [2011.10.20]
The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium. [2011.06]
Pharmacokinetics of dexrazoxane in subjects with impaired kidney function. [2011.05]
Safety of concurrent administration of dexrazoxane and doxorubicin in the canine cancer patient. [2010.12]
Good clinical and cost outcomes using dexrazoxane to treat accidental epirubicin extravasation. [2010.10]
Comparison of doxorubicin cardiotoxicity in pediatric sarcoma patients when given with dexrazoxane versus as continuous infusion. [2010.10]
Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. [2010.09.15]
Dexrazoxane for preventing anthracycline cardiotoxicity in children with solid tumors. [2010.09]
Successful dexrazoxane treatment of a potentially severe extravasation of concentrated doxorubicin. [2010.09]
Cardioprotective effect of dexrazoxane in a rat model of myocardial infarction: Anti-apoptosis and promoting angiogenesis. [2010.08.05]
The effect of dexrazoxane for clinical and subclinical cardiotoxicity in children with acute myeloid leukemia. [2010.05]
Successful experience utilizing dexrazoxane treatment for an anthracycline extravasation. [2010.05]
Sublethal doses of an anti-erbB2 antibody leads to death by apoptosis in cardiomyocytes sensitized by low prosenescent doses of epirubicin: the protective role of dexrazoxane. [2010.01]
Dexrazoxane protects the heart from acute doxorubicin-induced QT prolongation: a key role for I(Ks). [2010.01]
[Dexrazoxane in anthracycline induced cardiotoxicity and extravasation] [2010]
Dexrazoxane as a cardioprotectant in children receiving anthracyclines. [2010]
Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children
with high-risk acute lymphoblastic leukaemia: long-term follow-up of a
prospective, randomised, multicentre trial. [2010]
In vitro and in vivo study on the antioxidant activity of dexrazoxane. [2010]
Cardiac lesions induced by testosterone: protective effects of dexrazoxane and trimetazidine. [2009.06]
Dexrazoxane protects against doxorubicin-induced cardiomyopathy: upregulation of Akt and Erk phosphorylation in a rat model. [2009.01]
Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity. [2008.11]
Dexrazoxane (Totect): FDA review and approval for the treatment of accidental extravasation following intravenous anthracycline chemotherapy. [2008.04]
Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. [2008.03.01]
The use of dexrazoxane for the prevention of anthracycline extravasation injury. [2008.02]
Cardioprotective effect of dexrazoxane in patients with breast cancer treated with anthracyclines in adjuvant setting: a 10-year single institution experience. [2008]
Effects of dexrazoxane and amifostine on evolution of Doxorubicin cardiomyopathy in vivo. [2007.12]
Dexrazoxane for anthracycline extravasation. [2007.08]
Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats. [2007.07]
Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies. [2007.03]
Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. [2007.02.10]
Other uses of dexrazoxane: Savene, the first proven antidote against anthracycline extravasation injuries. [2007]
Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug? [2007]
Intrapleural extravasation of epirubicin, 5-fluouracil, and cyclophosphamide, treated with dexrazoxane. [2006.12]
Left ventricular systolic function assessed by echocardiography in children and adolescents with osteosarcoma treated with doxorubicin alone or in combination with dexrazoxane. [2006.12]
Prevention of chronic anthracycline cardiotoxicity in the adult Fischer 344 rat by dexrazoxane and effects on iron metabolism. [2006.10]
Feasibility of radiotherapy after high-dose dense chemotherapy with epirubicin, preceded by dexrazoxane, and paclitaxel for patients with high-risk Stage II-III breast cancer. [2006.07.15]
Treatment of anthracycline extravasation with dexrazoxane -- clinical experience. [2006.07]
Experimental study of dexrazoxane-anthracycline combinations using the model of isolated perfused rat heart. [2006.02.08]
Dexrazoxane use in the prevention of anthracycline extravasation injury. [2006.02]
Late anthracycline cardiotoxicity protection by dexrazoxane (ICRF-187) in pediatric patients: echocardiographic follow-up. [2006.02]
Suppression of mitoxantrone cardiotoxicity in multiple sclerosis patients by dexrazoxane. [2006.01]
Treatment of anthracycline extravasation in mice with dexrazoxane with or without DMSO and hydrocortisone. [2006.01]
[Subacute cardiotoxicity caused by anthracycline therapy in children: can dexrazoxane prevent this effect?] [2006]
[Dexrazoxane (ICRF-187)--a cardioprotectant and modulator of action of some anticancer drugs] [2006]
Cardioprotective effect of dexrazoxane during treatment with doxorubicin: a study using low-dose dobutamine stress echocardiography. [2005.12]
Long-term serial echocardiographic examination of late anthracycline cardiotoxicity and its prevention by dexrazoxane in paediatric patients. [2005.11]
Combining etoposide and dexrazoxane synergizes with radiotherapy and improves survival in mice with central nervous system tumors. [2005.09.15]
Dexrazoxane for the prevention of cardiomyopathy in anthracycline treated pediatric cancer patients. [2005.06.15]
Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin. [2005.05.15]
Desmopressin: in adults with nocturia. [2005]
Evaluating the role of dexrazoxane as a cardioprotectant in cancer patients receiving anthracyclines. [2004.11]
Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies. [2004.09]
[Dexrazoxane in patients with B-lymphomas or acute leukemias in the 2nd complete remission enables further therapy with cardiotoxic anthracyclines over recommended cumulative doses] [2004.06]
The cardioprotector dexrazoxane augments therapeutic efficacy of mitoxantrone in experimental autoimmune encephalomyelitis. [2004.01]
Pharmacokinetics of etoposide in cancer patients treated with high-dose etoposide and with dexrazoxane (ICRF-187) as a rescue agent. [2004.01]
The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review. [2004.01]
Dexrazoxane's protection of jejunal crypt cells in the jejunum of C3Hf/Kam mice from doxorubicin-induced toxicity. [2003.12]
High-dose epirubicin, preceded by dexrazoxane, given in combination with paclitaxel plus filgrastim provides an effective mobilizing regimen to support three courses of high-dose dense chemotherapy in patients with high-risk stage II-IIIA breast cancer. [2003.08]
Metabolism of dexrazoxane (ICRF-187) used as a rescue agent in cancer patients treated with high-dose etoposide. [2003.08]
Dexrazoxane in combination with anthracyclines lead to a synergistic cytotoxic response in acute myelogenous leukemia cell lines. [2003.07]
Dexrazoxane-a promising antidote in the treatment of accidental extravasation of anthracyclines. [2003]
The doxorubicin cardioprotective agent dexrazoxane (ICRF-187) induces endopolyploidy in rat neonatal myocytes through inhibition of DNA topoisomerase II. [2002.03]
Dexrazoxane (ICRF-187) protects cardiac myocytes against hypoxia-reoxygenation damage. [2002]
Acute dosage with dexrazoxane, but not doxorubicin, is associated with increased rates of hepatic protein synthesis in vivo. [2001.11]
High-dose doxorubicin, dexrazoxane, and GM-CSF in malignant mesothelioma: a phase II study-Cancer and Leukemia Group B 9631. [2001.11]
The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone-induced cardiotoxicity. [2001.10]
Modification of doxorubicin-induced cardiotoxicity: effect of essential fatty acids and ICRF-187 (dexrazoxane). [2001.07]
Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies. [2001.06]
Dexrazoxane significantly impairs the induction of doxorubicin resistance in the human leukaemia line, K562. [2001.04.06]
Signal-averaged electrocardiography in survivors of Hodgkin's disease treated with and without dexrazoxane. [2001]
The cardioprotective effect of the iron chelator dexrazoxane (ICRF-187) on anthracycline-mediated cardiotoxicity. [2000]
Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group. [1999.04]
Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer. [1999.03]
Plasmodium falciparum and Plasmodium yoelii: effect of the iron chelation prodrug dexrazoxane on in vitro cultures. [1999.02]
[Dexrazoxane. Current status and prospectives of cardiotoxicity of chemotherapy] [1999.01]
Coincident acute myelogenous leukemia and ischemic heart disease: use of the cardioprotectant dexrazoxane during induction chemotherapy. [1998.11]
Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy. [1998.09]
Antineoplastic activity of continuous exposure to dexrazoxane: potential new role as a novel topoisomerase II inhibitor. [1998.08]
|